MARKET WIREYahoo Finance • 11h ago
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On EarningsYahoo Finance report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
Why NBIX Stock slipped -0.19% Today — RQD Quant Desk Flash
$146.10 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $146.40
Neurocrine Biosciences Inc. (NBIX) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $14.88B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NBIX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NBIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Neurocrine Biosciences Inc. (NASDAQ: NBIX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $146.10 (-0.19% 1D, market cap $14.88B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, NBIX ranks #56 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NBIX compare to HALO and EXEL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NBIX carries a Roarable B (73/100 RQD), trailing P/E of 31.1x, gross margin of 96.0%, and ROIC of 15.7%. By comparison, HALO (Halozyme Therapeutics Inc.) holds a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B) and EXEL (Exelixis Inc.) posts a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NBIX?
▼
Per NBIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000914475), Neurocrine Biosciences Inc. generated $2.86B in revenue (+21.4% YoY), $478.6M in net income, and $748.7M in free cash flow against $4.63B in total assets and $620.3M in total debt. Key quantitative strengths: Strong cash generator (96% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $146.41 (+0.21%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 26.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+6.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NBIX)Realized 20D OHLCV Swing Band: ±4.5%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY NBIX SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 26.2% FCF Margin ($748.7M FCF) & 98.2% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)
Altman Z-Score 8.13 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)
Macro rate sensitivity & RSI-14 (56.1) create a -9 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$135.13+5.1% Next Q
65
Q2 (-2Q)Grade B-$142.00+2.8% Next Q
68
Q3 (-1Q)Grade B$146.00+0.1% Next Q
70
CurrentGrade B$146.10+7.1% Hist 90D α
73
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the NBIX Bull Thesis Could Fail
Even with a 73/100 (B) score, NBIX faces multiple-compression risk if 31.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 95.7% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($146.38) or 200D SMA ($147.51) invalidates the momentum regime and cuts Target Base ($155.96) toward Bear Floor ($119.80).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NBIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NBIX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NBIX Stock slipped -0.19% Today — RQD Quant Desk Flash
Neurocrine Biosciences Inc. (NBIX) slipped -0.19% to $146.10, trading at 37% of its 52-week range ($122.14 – $186.12). High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 37% of its 52-week range ($122.14 – $186.12) with RSI-14 at 56.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.5% around $146.10 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 98.2% gross margin and $748.7M annual free cash flow.
Live NBIX Headlines & Catalysts
MARKET WIREChartMill • 14h ago
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value StockChartMill report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 17h ago
Neurocrine Biosciences (Nasdaq:NBIX) - Stock AnalysisSimply Wall St report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Australia • 20h ago
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and historyYahoo Finance Australia report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 23h ago
Where Will Neurocrine Biosciences Be in 5 Years?The Motley Fool report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
CATALYSTGuruFocus • 1d ago
Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says UndervaluedGuruFocus report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Neurocrine Biosciences, Inc. Estimates – NASDAQ:NBIXTradingView report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts.Stock Titan report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
CATALYSTChartMill • 14h ago
Neurocrine Biosciences (NASDAQ:NBIX): A Debt-Free GARP Stock With Reasonable GrowthNeurocrine Biosciences fits a Peter Lynch GARP screen with strong profitability, zero debt, and a PEG below 1, balancing growth and valuation.
CATALYSTBenzinga • 1d ago
Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face TestApple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott International, Entergy,
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (NBIX Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NBIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.97%⚡ TESTING RESISTANCE
2026-11-02O $145.5H $146.4L $145.5C $146.1VOL 831.6K
RES: $148.7SUP: $126.3SMA50: $146.4SMA200: $147.5
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NBIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
24.0%/yr Implied 5Y Growth
vs. +21.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NBIX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NBIX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NBIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NBIX)
Health Care Rank #56 of 1016
⚔️ HALO vs NBIX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NBIX vs. HALO, EXEL, TWST, TECH)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Neurocrine Biosciences Inc. (NBIX) ranks #56 by composite RQD confidence (73/100, grade B) and #81 by equity capitalization ($14.88B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently holds the highest overall quantitative score in the immediate peer group at 89/100 (A) compared with NBIX at 73/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NBIX
ACTIVE
Neurocrine Biosciences Inc. | B | 73/100 | 31.1x | 96.0% | 15.7% | -0.19% | $14.88B | Benchmark Subject |
| HALO Halozyme Therapeutics Inc. | B | 75/100 | 47.0x | 83.6% | 18.0% | -0.21% | $14.89B | /halo-vs-nbix → |
| EXEL Exelixis Inc. | A | 89/100 | 21.0x | 96.0% | 35.1% | +4.82% | $16.40B | /exel-vs-nbix → |
| TWST Twist Bioscience Corporation | D+ | 52/100 | — | 94.2% | -11.7% | -11.92% | $11.50B | /twst-vs-nbix → |
| TECH Bio-Techne Corp | B | 72/100 | 155.3x | 64.8% | 3.4% | -0.07% | $11.40B | /tech-vs-nbix → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000914475In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neurocrine Biosciences Inc. (NBIX) reported GAAP revenue of $2.86B (+21.4% vs. FY2024 revenue of $2.36B , and +51.6% cumulative change since FY2023) , GAAP net income of $478.6M, operating cash flow of $782.7M, and free cash flow of $748.7M (+34.4% YoY). On the balance sheet, NBIX closed FY2025 with $4.63B in total assets against $620.3M in total debt (Altman Z-Score: 8.13, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.86B | $478.6M | $782.7M | $748.7M | $4.63B | $620.3M |
| FY2024 (FY) | 2024-12-31 | $2.36B | $341.3M | $595.4M | $557.2M | $3.72B | $508.1M |
| FY2023 (FY) | 2023-12-31 | $1.89B | $249.7M | $389.9M | $305.0M | $8.18B | $1.91B |
3. NBIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NBIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Neurocrine Biosciences Inc. (NASDAQ: NBIX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $146.10 (-0.19% 1D, market cap $14.88B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, NBIX ranks #56 in composite RQD confidence.
How does NBIX compare to HALO and EXEL in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NBIX carries a Roarable B (73/100 RQD), trailing P/E of 31.1x, gross margin of 96.0%, and ROIC of 15.7%. By comparison, HALO (Halozyme Therapeutics Inc.) holds a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B) and EXEL (Exelixis Inc.) posts a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NBIX?
Per NBIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000914475), Neurocrine Biosciences Inc. generated $2.86B in revenue (+21.4% YoY), $478.6M in net income, and $748.7M in free cash flow against $4.63B in total assets and $620.3M in total debt. Key quantitative strengths: Strong cash generator (96% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NBIX trading relative to its 50-day, 200-day, and 52-week technical levels?
NBIX last traded at $146.10 (-0.19% on volume of 1,322,851 shares), positioning the stock -0.19% below its 50-day simple moving average ($146.38) and -0.96% below its 200-day simple moving average ($147.51). Across its 52-week range of $122.14 to $186.12, NBIX sits at the 37.4% percentile with a 14-day RSI of 56.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.5% ($139.53 to $152.67).
NBIX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NBIX stock moving today?
Why NBIX Stock slipped -0.19% Today — RQD Quant Desk Flash. High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 73/100 (B)
✓ STAGE-C NUMBER FIREWALL VERIFIED
NBIX — Neurocrine Biosciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:14:44Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating is 73, graded B, with the verdict "Roarable Buy — Good Risk/Reward." Across the five pillars (per the Roarable RQD rating):
- Fundamental Cash Engine, 18/20: Supported by ROIC of 15.7% and an FCF yield of 5.03%. For a prospective investor, this pillar suggests the business converts capital into operating returns and generates free cash relative to its market value, which is the strongest single driver of the score.
- Whale 13F Flow, 11/20: Reflects institutional accumulation and options positioning. The moderate score indicates institutional interest is present but not dominant in the source data; holder-level detail is not available in source data.
- Insider Conviction, 15/20: Reflects SEC Form 4 and Congressional PTR cluster flow. A mid-high score suggests some insider activity supportive of the thesis, though the underlying trade detail is not available in source data.
- Macro Regime Fit, 11/20: Reflects a beta of 1.13 and sector sensitivity. This indicates the stock has modestly above-market price sensitivity, so drawdowns in risk-off regimes could be amplified relative to the broader market.
- Forensic Balance Sheet, 18/20: Supported by Altman Z of 8.13, Piotroski F of 9/9, and Debt/Equity of 0.18. For a prospective investor, this is the most conservative-leaning pillar, indicating low apparent financial distress risk.
Valuation tradeoffs: the stock trades at a P/E (TTM) of 31.1 and a forward P/E of 26.1 (per market data), so the rating's upside case depends on earnings growth continuing to compress the multiple. The rating is an analytical grade, not a recommendation to act.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $2860.5M | $619.1M | $478.6M | N/A | $748.7M | $713.0M | $620.3M |
| FY 2024 | $2355.3M | $570.5M | $341.3M | N/A | $557.2M | $233.0M | $508.1M |
| FY 2023 | $1887.1M | $250.9M | $249.7M | N/A | $305.0M | N/A | $1915.0M |
Revenue, operating income, net income, and free cash flow all rose across the three reported periods (per the SEC financials). Operating margin is 21.6% and net margin is 16.7% (per market data). Per the Roarable RQD rating, the Altman Z-Score is 8.13 and the Piotroski F-Score is 9/9, with Debt/Equity of 0.18; the balance sheet posture is therefore described as strong by these measures. Debt was $1915.0M in FY 2023 and $620.3M in FY 2025 (per SEC financials).
Recent Catalysts & News Wire Analysis
- Multiple coverage items (Yahoo Finance, ChartMill, Simply Wall St, Yahoo Finance Australia, The Motley Fool, GuruFocus) reference the stock trading and valuation, with headlines variously describing it as trading below fair value, a decent value stock, and undervalued after a 4.4% drop. These are headline characterizations only; underlying analysis is not provided.
- The GuruFocus item carries a GREEN light tagged CATALYST; the remaining items are YELLOW, tagged MARKET WIRE.
- Risk watch items: the source data contains no specific regulatory, clinical, or litigation events.
- Proprietary signals: none (per the Butterfly Supply-Chain Graph).
Open Questions
- What specific products and revenue sources drive the reported revenue growth, and how concentrated are they?
- What is the EPS for each reported fiscal year, given that EPS is N/A across the financial periods?
- What drove the FY 2023 debt level of $1915.0M and its reduction to $620.3M by FY 2025?
- What institutional, insider, and Congressional holdings and trades underpin the 11/20 whale and 15/20 insider pillar scores?
- What pipeline, regulatory, or competitive catalysts could affect the forward P/E of 26.1?
NBIX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Neurocrine Biosciences Inc. (NBIX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 11h ago
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings Yahoo Finance report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 14h ago
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock ChartMill report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 17h ago
Neurocrine Biosciences (Nasdaq:NBIX) - Stock Analysis Simply Wall St report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Australia • 20h ago
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history Yahoo Finance Australia report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 23h ago
Where Will Neurocrine Biosciences Be in 5 Years? The Motley Fool report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 1d ago
Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued GuruFocus report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Neurocrine Biosciences, Inc. Estimates – NASDAQ:NBIX TradingView report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts. Stock Titan report covering Neurocrine Biosciences Inc. (NBIX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NBIX Bull vs. Bear Conversation Board — What's Your Call at $146.10?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NBIX 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $172.73 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is NBIX (B • RQD 73/100) a Buy at $146.38?
Welcome to the NBIX (Neurocrine Biosciences Inc.) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (15.7% ROIC), while bears focus on valuation multiple compression (31.1x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $115.64 (-21.0%)
Spot @ $146.38 Pump the brakes on NBIX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on NBIX, but look at what you are paying: 31.1x trailing P/E with 96.0% gross margins. Unless Neurocrine Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $166.87 (+14.0%)
Spot @ $146.38 NBIX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on NBIX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $146.38 (52-wk range $122.14 - $186.12), any beat on forward guidance forces shorts and underweight funds to chase.